Ahead of the company’s upcoming investor conference presentations next week, CorMedix (CRMD) also maintains its FY27 DefenCath sales outlook of $150M-$170M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix price target lowered to $13 from $15 at Leerink
- Buy Rating Maintained as Long-Term Rezzayo Upside Remains Underappreciated Despite Near-Term Weakness
- CorMedix reports Q4 EPS 16c vs 20c last year
- CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Low P/E Alert! These 3 Undervalued Stocks Are Poised to Surge Over 90%